Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, Anh DD, Baiqing D, Bhutta Z, Sur D, Whittington D. Cost of illness due to typhoid fever in five Asian countries. Trop Med Int Health. 2011 Mar 1;16(3):314-23.
Von Scheele BG, Martin RD, Gilsenan AW, Ceberg J, Andrews EB, Masica D, Alvegård T. The European postmarketing adult osteosarcoma surveillance study characteristics of patients: a preliminary report. Acta Orthop. 2009;80:67-74.
Clarkson T, Anthony MS, Hughes C. Estrogenic soybean isoflavones and chronic disease: risks and benefits. Trends Endocrinol Metab. 1995 Jan;6(1):11-6.